Matches 1 - 50 out of 433 1 2 3 4 5 6 7 8 9 >


Match Document Document Title
US20140050739 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS  
The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation...
US20120101026 Compounds For Enzyme Inhibition  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
US20080124322 Activation and inhibition of the immune system  
Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator...
US20070149454 Controlled Release Delivery System for Nasal Applications and Method of Treatment  
This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or...
US20070060527 Orally administered small peptides synergize statin activity  
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are...
US20120302493 Cyclic Peptides As G-Protein Coupled Receptor Antagonists  
The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred...
US20110288011 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF  
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell...
US20110015131 METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE (AD)  
The present invention relates to methods for preventing Alzheimer's disease (AD) with an Aβ42 mimotope and binds to an antibody specific for DAEFRH (SEQ ID NO: 1) which is a part of the...
US20080132450 Pharmaceutical composition for suppression of apoptosis and method for delivering the same  
The present invention relates to a pharmaceutical composition for treating heart diseases, neurodegenerative diseases, and diseases and conditions caused by apoptosis, which contains a conjugate...
US20070287662 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress  
An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily...
US20070191272 Proteinaceous pharmaceuticals and uses thereof  
The present invention provides cysteine-containing scaffolds and/or proteins, expression vectors, host cell and display systems harboring and/or expressing such cysteine-containing products. The...
US20060276393 Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders  
Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a...
US20060154865 Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)  
A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up...
US20060153801 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same  
A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may...
US20060025337 Sirtuin related therapeutics and diagnostics for neurodegenerative diseases  
Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and...
US20050137142 Combinations useful for the treatment of neuronal disorders  
The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically...
US20160376335 POLYMERS CONTAINING MULTIVALENT AMYLOID-BETA-BINDING D-PEPTIDES AND THEIR USE  
The invention relates to novel multivalent polymeric amyloid-beta-binding substances composed of several interconnected substances which per se already have amyloid-beta-binding properties, and to...
US20150174267 COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS  
The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a...
US20150174266 APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER  
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as...
US20140086937 IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO  
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a...
US20140044725 ALZHEIMER'S DISEASE TREATMENT METHOD  
The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody...
US20100331237 GAG BINDING PROTEINS  
A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenanceintroducing at least...
US20080096818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE  
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce...
US20060241038 Therapeutic agent for Abeta related disorders  
The present invention provides a pharmaceutical composition comprising at least one member selected from a compound capable of enhancing Aβ37 production, a compound capable of inhibiting Aβ40 and...
US20060228371 Immunological control of beta-amyloid levels in vivo  
An antibody and vectorized antibody, capable of crossing the blood brain barrier, which catalyze hydrolysis of β-amyloid at a predetermined amide linkage are described. The antibody preferentially...
US20050181037 Cardiolipin compositions their methods of preparation and use  
The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation. The reaction schemes can...
US20050014697 Compositions and methods for modulating S-nitrosoglutathione reductase  
Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion...
US20160058874 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY  
Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system...
US20150315237 NMDA Receptor Modulators and Uses Thereof  
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning,...
US20140107037 METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, OR OTHER DISORDERS  
The disclosure relates, at least in part, to methods of treating autism in a patient in need thereof by administering an effective amount of a disclosed compound, e.g., a NMDA receptor glycine...
US20120101025 Compounds For Enzyme Inhibition  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
US20120039991 USE OF APOPTOSIS INHIBITING COMPOUNDS IN DEGENERATIVE NEUROLOGICAL DISORDERS  
The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases...
US20110201558 Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain  
The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an...
US20100331236 CYCLIC PEPTIDES AS G-PROTEIN COUPLED RECEPTOR ANTAGONISTS  
The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred...
US20100233095 CONFORMATIONALLY DYNAMIC PEPTIDES  
Disclosed are novel peptides that are useful, for example, for detecting target proteins having a β-sheet secondary structure which may be associated with a disease, and for diagnosing and...
US20080153743 METHODS RELATING TO THE TREATMENT OF FIBROSIS  
The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The...
US20080019986 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof  
This invention provides a method of inhibiting the binding of a β-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding inhibiting amount of a compound...
US20070254835 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS  
Compositions, kits and methods are provided for treating or preventing neurological disorders associated with aberrant silencing of gene expression by reestablishing the gene expression through...
US20060229233 Compositions and methods for treating neurological disorders  
Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic...
US20060154871 Peptides  
The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous...
US20050043242 Method for treating or preventing Alzheimer's disease  
Disclosed is a method for treating or preventing Alzheimer's disease by restricting the level of metabolizable carbohydrate in the diet and/or administering to the patient an effective amount of...
US20110312878 PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS  
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a...
US20110306558 PROSAPOSIN AS A NEUROTROPHIC FACTOR  
Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is...
US20080227719 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE  
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce...
US20080020018 Combination Products  
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active...
US20070082848 VEGF-C or VEGF-D materials and methods for treatment of neuropathologies  
The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells and materials and methods for administering said cells to...
US20050059591 Prevention and treatment of amyloidogenic disease  
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce...
US20140057834 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway  
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
US20110258713 COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION  
The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular,...
US20080096796 Peptides That Stimulate Cell Survival and Axon Regeneration  
Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa (SEQ.ID.NO.: 1) in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any...

Matches 1 - 50 out of 433 1 2 3 4 5 6 7 8 9 >